CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Millions, unless otherwise specified	Jun. 30, 2013		Dec. 31, 2012
Assets
Cash and cash equivalents	$ 2,436		$ 10,081
Short-term investments	31,275		22,318
Accounts receivable, less allowance for doubtful accounts	11,523		11,456
Inventories	6,282		6,076
Taxes and other current assets	9,819		8,956
Assets of discontinued operations and other assets held for sale	100		5,944
Total current assets	61,435		64,831
Long-term investments	16,107		14,149
Property, plant and equipment, less accumulated depreciation	12,443		13,213
Goodwill	42,431		43,661
Identifiable intangible assets, less accumulated amortization	41,776	[1]	45,146	[1]
Taxes and other noncurrent assets	5,143		4,798
Total assets	179,335		185,798
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt	5,214	[2],[3]	6,424	[2],[3]
Accounts payable	1,978		2,921
Dividends payable	1,685		1,733
Income taxes payable	904		979
Accrued compensation and related items	1,430		1,875
Other current liabilities	12,218		13,812
Liabilities of discontinued operations	21		1,442
Total current liabilities	23,450		29,186
Long-term debt	31,532	[2],[4]	31,036	[2],[4]
Pension benefit obligations	7,534		7,782
Postretirement benefit obligations	3,454		3,491
Noncurrent deferred tax liabilities	22,338		21,193
Other taxes payable	6,819		6,581
Other noncurrent liabilities	5,231		4,851
Total liabilities	100,358		104,120
Commitments and Contingencies
Preferred stock	36		39
Common stock	451		448
Additional paid-in capital	76,412		72,608
Treasury stock	(59,515)		(40,122)
Retained earnings	67,628		54,240
Accumulated other comprehensive loss	(6,465)		(5,953)
Total Pfizer Inc. shareholders’ equity	78,547		81,260
Equity attributable to noncontrolling interests	430		418
Total equity	78,977		81,678
Total liabilities and equity	$ 179,335		$ 185,798

[1] The decrease is primarily related to amortization, asset impairment charges and the transfer of certain product rights to our equity-method investment in China. For additional information about the asset impairment charges, see Note 4. Other (Income)/Deductions—Net. For additional information about the transfer of certain product rights, see Note 2D. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Equity-Method Investment.

[2] Some carrying amounts may include adjustments for discount or premium amortization or for the effect of interest rate swaps designated as hedges.

[3] The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost and short-term borrowings not measured at fair value on a recurring basis were not significant as of June 30, 2013 or December 31, 2012. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities at cost are based on Level 3 inputs, using a market approach.

[4] Includes foreign currency debt with fair values of $699 million as of June 30, 2013 and $809 million as of December 31, 2012, which are used as hedging instruments.